Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone434-422-9800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
Next Earnings Date3/20/2019 (Estimated)
OptionableNot Optionable
Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions
What is Adial Pharmaceuticals' stock symbol?
Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."
When is Adial Pharmaceuticals' next earnings date?
What price target have analysts set for ADIL?
2 brokers have issued 1 year price targets for Adial Pharmaceuticals' shares. Their predictions range from $5.00 to $5.00. On average, they anticipate Adial Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 66.1% from the stock's current price. View Analyst Price Targets for Adial Pharmaceuticals.
What is the consensus analysts' recommendation for Adial Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adial Pharmaceuticals.
Has Adial Pharmaceuticals been receiving favorable news coverage?
Press coverage about ADIL stock has trended somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adial Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Are investors shorting Adial Pharmaceuticals?
Adial Pharmaceuticals saw a decrease in short interest during the month of February. As of February 28th, there was short interest totalling 236,054 shares, a decrease of 59.3% from the February 15th total of 579,355 shares. Based on an average trading volume of 1,143,958 shares, the short-interest ratio is currently 0.2 days. Currently, 3.4% of the company's stock are sold short. View Adial Pharmaceuticals' Current Options Chain.
Who are some of Adial Pharmaceuticals' key competitors?
Some companies that are related to Adial Pharmaceuticals include XOMA (XOMA), RenovaCare (RCAR), Trevena (TRVN), Unum Therapeutics (UMRX), Sol Gel Technologies (SLGL), Hamilton Thorne (HTL), Mersana Therapeutics (MRSN), Corvus Pharmaceuticals (CRVS), Sensus Healthcare (SRTS), NantHealth (NH), Nymox Pharmaceutical (NYMX), Equillium (EQ), OASMIA PHARMACE/ADR (OASM), Circassia Pharmaceuticals (CIR) and Imprimis Pharmaceuticals (IMMY).
What other stocks do shareholders of Adial Pharmaceuticals own?
Who are Adial Pharmaceuticals' key executives?
Adial Pharmaceuticals' management team includes the folowing people:
- Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)
- Mr. Joseph M. Truluck MBA, CFO & COO (Age 41)
- Dr. Tomasz H. Zastawny Ph.D., DSc, Chief Devel. Officer
- Ms. Monika Z. Rogozinska, Sr. VP of Drug & Bus. Devel.
- Mr. Lawrence Goldman, Controller (Age 63)
When did Adial Pharmaceuticals IPO?
(ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.
When did Adial Pharmaceuticals' lock-up period expire?
Adial Pharmaceuticals' lock-up period expired on Wednesday, January 23rd. Adial Pharmaceuticals had issued 1,464,000 shares in its initial public offering on July 27th. The total size of the offering was $7,320,000 based on an initial share price of $5.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.
Who are Adial Pharmaceuticals' major shareholders?
Adial Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.14%), Geode Capital Management LLC (0.21%), Geode Capital Management LLC (0.19%) and Two Sigma Investments LP (0.18%).
Which major investors are buying Adial Pharmaceuticals stock?
ADIL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Geode Capital Management LLC and Two Sigma Investments LP.
How do I buy shares of Adial Pharmaceuticals?
Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adial Pharmaceuticals' stock price today?
One share of ADIL stock can currently be purchased for approximately $3.01.
How big of a company is Adial Pharmaceuticals?
Adial Pharmaceuticals has a market capitalization of $29.21 million. Adial Pharmaceuticals employs 3 workers across the globe.
What is Adial Pharmaceuticals' official website?
How can I contact Adial Pharmaceuticals?
Adial Pharmaceuticals' mailing address is 1001 RESEARCH PARK BLVD. SUITE 100, CHARLOTTESVILLE VA, 22911. The company can be reached via phone at 434-422-9800 or via email at [email protected]
MarketBeat Community Rating for Adial Pharmaceuticals (NASDAQ ADIL)
MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
